Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):223–229. doi: 10.1097/QAI.0b013e318218e068

Table 1.

Comparison of population with antiretroviral treatment interruption (TI) (N=101) to population that initiated but never interrupted antiretroviral treatment (N=343)

Characteristic
 TI N=101
 No TI N=343
 P-value
Sex
    Male 40 (40) 166 (48) 0.14
    Female
 61 (60)
 177 (52)
  
Birth Cohort
    1991-1993 41 (40) 62 (18)
    1994-1995 30 (30) 87 (25) <0.0001
    1996-1997 17 (17) 74 (22)
    1998-2002
 13 (13)
 120 (35)
  
Race
    Black 72 (71) 248 (72) 0.14
    Not Black 20 (20) 81 (24)
    Unknown
 9 (9)
 14 (4)
  
Ethnicity
    Hispanic 26 (26) 81 (24) 0.24
    Not Hispanic 74 (73) 262 (76)
    Unknown
 1 (1)
 0 (0)
  
Age at ART initiation (years), Median (Q1, Q3)
 1.0 (0.4, 2.3)
 0.8 (0.3, 2.6)
 0.60
CDC Class at AMP Entry 46 (45) 167 (49) 0.92
    N/A 28 (28) 93 (27)
    B 26 (26) 80 (23)
    C 1 (1) 3 (1)
    Missing